We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Oral Antibody Test for HIV Approved for Consumers

By LabMedica International staff writers
Posted on 28 May 2012
A rapid mouth swab test to diagnose human immunodeficiency virus (HIV) infection is being available as an over-the-counter product. More...


The test is a noninvasive, quick, accurate way to test for HIV-1 antibodies without blood, needles, or lancets, only takes about 20 minutes and is a home version of a rapid HIV test already being used by health care professionals in community settings.

The US Food and Drug Administration (FDA; Silver Springs, MD, USA) have approved the OraQuick At-Home HIV test which was extensively tested before marketing. In clinical trials enrolling regular people at risk of HIV infection, some 7% of people with HIV infection are wrongly told they do not have HIV. With a professional test, that happens only 2% of the time. Studies show the test was less accurate when consumers used them, but the FDA says the benefits of expanding HIV testing outweigh that test accuracy. The OraQuick system draws HIV antibodies out of the tissues of the cheek and gum. The virus itself is rarely ever found in oral fluid.

The price tag of the at-home test has not yet been set but will be a good bit more than the USD 20 cost of the professional version. That is partly because it will come with a detailed instruction booklet, and because OraSure (Bethlehem, PA, USA) the company making the test, will set up a call center with trained counselors available 24 hours a day, seven days a week. Stephen R. Lee, PhD, OraSure executive vice president and chief science officer, said, "The price will be substantially lower than USD 60, probably nearer USD 35."

The FDA calculates that in the first year after OraQuick is approved for home use, an extra 45,000 people will correctly learn they have HIV. The US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) estimates that there are 50,000 new HIV infections every year. About 1.2 million Americans are HIV-infected, and about one out of five do not know they carry the virus. Such people may be more likely to spread the virus than those who know they are infected.

Susan Buchbinder, MD, director of HIV research at San Francisco's health department (CA, USA), said, "A positive HIV test does reduce risk behavior. A negative test doesn't have much of an influence. We must assume there will be some incorrect results. The question is how do we help people understand a negative result might not truly mean a person is negative for HIV."

Related Links:

US Food and Drug Administration
OraSure
US Centers for Disease Control and Prevention



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.